Alborz Bulk Pharmaceutical Company
Alborz Bulk Pharmaceutical Company is an Iran Fara Bourse-listed manufacturer of active pharmaceutical ingredients and pharmaceutical raw materials. Controlled by Alborz Investment Group, it is headquartered in Tehran and operates a Saveh production site supplying Iranian drug formulators. The business is relevant to pharmaceutical supply-chain, import-substitution and API procurement analysis.
Market position
A domestic API synthesis supplier serving Iran’s finished-dose pharmaceutical industry, with production spanning general, antibiotic and steroid APIs.
Operations & footprint
Products and services
Alborz Bulk Pharmaceutical Company develops and manufactures active pharmaceutical ingredients and pharmaceutical raw materials for domestic and regional pharmaceutical manufacturers. Its product portfolio includes cardiovascular APIs such as atorvastatin, losartan and metoprolol tartrate; analgesic APIs including naproxen and ibuprofen; neurological and psychiatric ingredients such as carbamazepine, gabapentin and citalopram; and additional APIs including cefixime, dexamethasone, betamethasone, prednisolone, metformin, gemfibrozil, dextromethorphan and other pharmaceutical intermediates.
Operations and assets
The company operates a 20,000 m² industrial production site in Kaveh Industrial City, Saveh, Markazi Province, supported by on-site analytical and synthesis R&;D laboratories. Manufacturing is conducted under national GMP requirements supervised by Iran’s Food and Drug Administration.
Geographic footprint
Head office in Tehran, Tehran Province; manufacturing in Kaveh Industrial City, Saveh, Markazi Province. Sales are primarily to Iranian pharmaceutical manufacturers.
Ownership & group structure
Ownership
Alborz Investment Group is the controlling shareholder. The company sits within the broader Barekat Pharmaceutical Group, Tadbir Economic Development Group and Setad Executing the Order of Imam (EIKO) corporate network; remaining shares are held by public retail and institutional investors through the Iran Fara Bourse.
Parent company
Alborz Investment Group (والبرز).
Reported scale
Employees: 80–150 employees across plant operations and headquarters. Scale note: For the six months ended 22 September 2024, sales revenue exceeded IRR 3.37 trillion (approximately IRR 337 billion tomans).
Commercial and investment relevance
Alborz Bulk is relevant for investors assessing Iran's pharmaceutical API market, import substitution, raw-material security, local synthesis capability, medicine supply resilience, regional pharmaceutical exports, and upstream exposure to the healthcare industry. It can support analysis of where Iran remains dependent on imported APIs, where local manufacturers can substitute foreign supply, and how currency volatility affects API margins and downstream medicine pricing. Due diligence should review current IFB and Codal disclosures, ownership within Alborz Investment Group, product registrations, GMP and quality certifications, API portfolio, utilization rates, Kaveh Industrial City production lines, raw-material imports, export destinations, customer concentration, R&;D pipeline, environmental and occupational compliance, price regulation, and technology dependence. Alborz Bulk supplies upstream inputs to domestic drug formulators, including companies within the Alborz Investment Group and Barekat Pharmaceutical Group networks as well as independent manufacturers. Its local API production supports continuity of medicine manufacturing and reduces reliance on imported finished API supplies.
Constraints, risk & compliance
Key risks and constraints
About half of chemical intermediates, active precursors and organic solvents are imported, leaving production economics and supply continuity exposed to cross-border procurement conditions. The company’s predominantly domestic sales base also concentrates demand in Iran’s regulated pharmaceutical market.
Sanctions and compliance considerations
The company’s corporate network includes Barekat Pharmaceutical Group and Setad Executing the Order of Imam (EIKO), which are subject to US sanctions frameworks. Pharmaceutical trade may qualify for humanitarian exemptions, but banking, chemical logistics and technology procurement can face enhanced compliance screening and transaction friction.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around Alborz Bulk Pharmaceutical Company. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does Alborz Bulk Pharmaceutical Company produce?
It manufactures active pharmaceutical ingredients and pharmaceutical raw materials, including general APIs, cefixime and cephalosporin intermediates, and steroid APIs.
Where are Alborz Bulk’s operations located?
The company is headquartered in Tehran and operates its manufacturing site in Kaveh Industrial City, Saveh, Markazi Province.
Is Alborz Bulk Pharmaceutical Company publicly listed?
Yes. It is listed on the Iran Fara Bourse under the ticker دبالک (DBAL1).
Who controls Alborz Bulk Pharmaceutical Company?
Alborz Investment Group is the controlling shareholder, within the broader Barekat Pharmaceutical Group, Tadbir Economic Development Group and EIKO corporate network.